Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...

BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...

BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally "hard-to-drug" targets, announced today a strategic collaboration and licensing agreement with Takeda.

BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...

Privately-held BridGene Biosciences has announced a strategic collaboration and licensing agreement with Japan’s Takeda. The ...

In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...

Bridgene Biosciences Inc. has signed a strategic collaboration and licensing agreement with Takeda Pharmaceutical Co. Ltd. to discover small-molecule drug candidates against targets in immunology and ...

Kangpu Biopharmaceuticals, Ltd. ("Kangpu") today announced that the Company has received IND approval from the CDE (Center for Drug Evaluation) of China National Medical Products Administration (NMPA) ...

Virginia Cancer Specialists, a respected leader in providing community-based cancer care in Northern VA for more than ...

Neurodevelopmental disorders company GRIN Therapeutics, an affiliate of the Blackstone Life Sciences portfolio company ...

Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the plug on the program after the FDA pointed out the shortcomings of its ...